|
KR20190103320A
|
|
Therapeutic Therapy for the Treatment of Fabry with Stabilized Alpha-galactosidase
|
|
BR112017014433A2
|
|
modified dnase i protein, process for preparing modified dnase i protein and pharmaceutical composition
|
|
US2016053247A1
|
|
Stabilized alpha-galactosidase and uses thereof
|
|
US2016075754A1
|
|
Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
|
|
US2017101633A1
|
|
Method of maintaining disease stability in a subject having gaucher's disease
|
|
CN105164151A
|
|
TNF alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
|
|
CN104245725A
|
|
Oral unit dosage forms and uses of same for the treatment of gaucher disease
|
|
EP2809780A1
|
|
Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
|
|
AU2012241058A1
|
|
Mucosal or Enteral Administration of Biologically Active Macromolecules
|
|
KR20140015330A
|
|
Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
|
|
SI2865751T1
|
|
Stabilized alpha-galactosidase and uses thereof
|
|
EP2542572A2
|
|
Multimeric forms of therapeutic proteins and uses thereof
|
|
HU1000021D0
|
|
Disposable device, battery and method for axenic culturing and harvesting cells and/or tissue in consecutive cycles
|
|
EP2192924A2
|
|
Saccharide-containing protein conjugates and uses thereof
|
|
CN101861382A
|
|
Large scale disposable bioreactor
|
|
AU2007201909A1
|
|
Production of High Mannose Proteins in Plant Culture
|
|
US2008038232A1
|
|
Human lysosomal proteins from plant cell culture
|
|
AU2006271181A1
|
|
Mucosal or enteral administration of biologically active macromolecules
|
|
WO2006040764A2
|
|
System and method for production of antibodies in plant cell culture
|
